National Cancer Institute; Notice of Closed Meetings, 44274 [2010-18498]

Download as PDF 44274 Federal Register / Vol. 75, No. 144 / Wednesday, July 28, 2010 / Notices Dated: July 22, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–18508 Filed 7–27–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, October 21, 2010, 8 a.m. to October 21, 2010, 5 p.m., Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD, 20814 which was published in the Federal Register on July 9, 2010, 75 FR 39547. This FRN amendment has been processed to change the location of this meeting from the Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda MD 20814 to the Legacy Hotel and Meeting Center, 1775 Rockville Pike, Rockville MD 20852. The meeting is closed to the public. Dated: July 22, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–18503 Filed 7–27–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health sroberts on DSKD5P82C1PROD with NOTICES National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. VerDate Mar<15>2010 19:05 Jul 27, 2010 Jkt 220001 Name of Committee: National Cancer Institute Special Emphasis Panel, Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer. Date: August 31, 2010. Time: 12 p.m. to 1:30 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6116 Executive Boulevard, Room 210, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Kenneth L. Bielat, PhD, Scientific Review Officer, Special Review Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7147, Bethesda, MD 20892–8329, 301–496–7576, bielatk@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Basic, Translational and Clinical Oncology. Date: September 28–29, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel & Executive Meeting Ctr. Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: David G. Ransom, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd, Rm 8133, Bethesda, MD 20892–8328, 301–451–4757, david.ransom@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Drug Discovery, Biomarkers, Therapeutics. Date: September 28–29, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Peter J. Wirth, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8129, Bethesda, MD 20892–8328, 301–496–7565, pw2q@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: July 22, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–18498 Filed 7–27–10; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Use of Leptin and Leptin Analogs for the Treatment of Lipodystrophy National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent Application No. 60/336,394, filed on October 22, 2001 (HHS Ref. No. E–064–2004/0–US– 01); PCT Application No. PCT/US02/ 033875, filed on October 22, 2002 (HHS Ref. No. E–064–2004/0–PCT–02); U.S. Patent Application No. 10/279,129, filed on October 22, 2002 (HHS Ref. No. E– 064–2004/0–US–03); Japanese Patent Application No. 2003–537565, filed on October 22, 2002 (HHS Ref. No. E–064– 2004/0–JP–04); Mexican Patent No. 250445, filed on October 22, 2002 and granted on October 16, 2007 (HHS Ref. No. E–064–2004/0–MX–05); Polish Patent Application No. P–374301, filed on October 22, 2002 (HHS Ref. No. E– 064–2004/0–PL–6); Canadian Patent Application No. 2464277, filed on October 22, 2002 (HHS Ref. No. E–064– 2004/0–CA–07); European Patent Application No. 02793811.7, filed on October 22, 2002 (HHS Ref. No. E–064– 2004/0–EP–08); U.S. Patent No. 7,183,254, filed on July 18, 2003 and granted on 2/27/2007 (HHS Ref. No. E– 064–2004/0–US–09); U.S. Patent Application No. 11/606,805, filed on October 29, 2006 (HHS Ref. No. E–064– 2004/0–US–10); Mexican Patent Application No. 2007/006095, filed on May 14, 2007 (HHS Ref. No. E–064– 2004/0–MX–11); Australian Patent Application No. 2002359288, filed on October 22, 2002 (HHS Ref. No. E–064– 2004/0–AU–12); Hong Kong Patent Application No. 4106574.7, filed on September 1, 2004 (HHS Ref. No. E– 064–2004/0–HK–13); European Patent Application No. 10165256.8, filed on June 8, 2010 (HHS Ref. No. E–064–2004/ 0–EP–14); and Japanese Patent Application No. 2010–137501, filed on June 16, 2010 (HHS Ref. No. E–064– 2004/0–JP–15), all entitled ‘‘Use of Leptin for Treating Human Lipoatrophy and Method of Determining Predisposition to Said Treatment’’, to SUMMARY: E:\FR\FM\28JYN1.SGM 28JYN1

Agencies

[Federal Register Volume 75, Number 144 (Wednesday, July 28, 2010)]
[Notices]
[Page 44274]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-18498]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Nanotechnology Imaging and Sensing Platforms for Improved 
Diagnosis of Cancer.
    Date: August 31, 2010.
    Time: 12 p.m. to 1:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6116 Executive Boulevard, 
Room 210, Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Kenneth L. Bielat, PhD, Scientific Review 
Officer, Special Review Logistics Branch, Division of Extramural 
Activities, National Cancer Institute, 6116 Executive Boulevard, 
Room 7147, Bethesda, MD 20892-8329, 301-496-7576, 
bielatk@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Basic, Translational and Clinical Oncology.
    Date: September 28-29, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Doubletree Hotel & Executive Meeting Ctr. Bethesda, 8120 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: David G. Ransom, PhD, Scientific Review Officer, 
Research Programs Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 6116 Executive Blvd, Rm 8133, 
Bethesda, MD 20892-8328, 301-451-4757, david.ransom@nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Drug Discovery, Biomarkers, Therapeutics.
    Date: September 28-29, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 
8120 Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Peter J. Wirth, PhD, Scientific Review Officer, 
Research Programs Review Branch, Division of Extramural Activities, 
National Cancer Institute, 6116 Executive Boulevard, Room 8129, 
Bethesda, MD 20892-8328, 301-496-7565, pw2q@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: July 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-18498 Filed 7-27-10; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.